NHLBI in late January put out an RFP for the program, which calls for researchers to develop proteomics technologies and apply them to solve clinical puzzles. It is set to begin early next year, shortly after its current two major proteomics initiatives expire.
The deal brings to six the number of academic institutions from which Fate has licensed IP related to using small molecules to induce pluripotency in stem cells for therapeutic effect, drug discovery, and matched cell-replacement therapies.
Genentech developed Unison to reduce the amount of time researchers spent on data preparation prior to bioinformatics analysis. Recognizing that many scientists outside the company are grappling with the same issues, they decided to release the system under the open-source Academic Free License.
The panel of proteomics experts told attendees of the annual meeting of the US Human Proteome Organization that the science is not ready for clinical use and the discipline has become marginalized compared to genomics.
Some researchers, like Ruedi Aebersold, claim that because tools such as mass specs are in a "perpetual discovery mode, the high-performance application of the [the tools] will remain in specialized labs."